Richard Sheppard1, Eileen Hsich2, Julie Damp2, Uri Elkayam2, Angela Kealey2, Gautam Ramani2, Mark Zucker2, Jeffrey D Alexis2, Benjamin D Horne2, Karen Hanley-Yanez2, Jessica Pisarcik2, Indrani Halder2, James D Fett2, Dennis M McNamara2. 1. From the Division of Cardiology, Jewish General Hospital, McGill University, Montreal, QC, Canada (R.S.); Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH (E.H.); Department of Cardiology, Vanderbilt University, Nashville, TN (J.D.); Division of Cardiovascular Medicine, University of Southern California, Los Angeles (U.E.); Department of Medicine and Cardiovascular Sciences, University of Calgary, Calgary, AB, Canada (A.K.); Department of Cardiology, University of Maryland, Baltimore (G.R.); Cardiac Transplant Center, Beth Israel Newark Medical Center, NJ (M.Z.); Department of Cardiology, University of Rochester, NY (J.D.A.); Division of Cardiology, Intermountain Medical Center, Salt Lake City, Utah (B.D.H.); and Division of Cardiology, Heart, Lung, Blood, and Vascular Medicine Institute, University of Pittsburgh, PA (K.H.-Y., J.P., I.H., J.D.F., D.M.M.N.). richard.sheppard@mcgill.ca. 2. From the Division of Cardiology, Jewish General Hospital, McGill University, Montreal, QC, Canada (R.S.); Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH (E.H.); Department of Cardiology, Vanderbilt University, Nashville, TN (J.D.); Division of Cardiovascular Medicine, University of Southern California, Los Angeles (U.E.); Department of Medicine and Cardiovascular Sciences, University of Calgary, Calgary, AB, Canada (A.K.); Department of Cardiology, University of Maryland, Baltimore (G.R.); Cardiac Transplant Center, Beth Israel Newark Medical Center, NJ (M.Z.); Department of Cardiology, University of Rochester, NY (J.D.A.); Division of Cardiology, Intermountain Medical Center, Salt Lake City, Utah (B.D.H.); and Division of Cardiology, Heart, Lung, Blood, and Vascular Medicine Institute, University of Pittsburgh, PA (K.H.-Y., J.P., I.H., J.D.F., D.M.M.N.).
Abstract
BACKGROUND: Black women are at greater risk for peripartum cardiomyopathy (PPCM). The guanine nucleotide-binding proteins β-3 subunit (GNB3) has a polymorphism C825T. The GNB3 TT genotype more prevalent in blacks is associated with poorer outcomes. We evaluated GNB3 genotype and myocardial recovery in PPCM. METHODS AND RESULTS: A total of 97 women with PPCM were enrolled and genotyped for the GNB3 T/C polymorphism. Left ventricular ejection fraction (LVEF) was assessed by echocardiography at entry, 6 and 12 months postpartum. LVEF over time in subjects with the GNB3 TT genotype was compared with those with the C allele overall and in black and white subsets. The cohort was 30% black, age 30+6, LVEF 0.34+0.10 at entry 31+25 days postpartum. The % GNB3 genotype for TT/CT/CC=23/41/36 and differed markedly by race (blacks=52/38/10 versus whites=10/44/46, P<0.001). In subjects with the TT genotype, LVEF at entry was lower (TT=0.31+0.09; CT+CC=0.35+0.09, P=0.054) and this difference increased at 6 (TT=0.45+0.15; CT+CC=0.53+0.08, P=0.002) and 12 months (TT=0.45+0.15; CT+CC=0.56+0.07, P<0.001.). The difference in LVEF at 12 months by genotype was most pronounced in blacks (12 months LVEF for GNB3 TT=0.39+0.16; versus CT+CC=0.53+0.09, P=0.02) but evident in whites (TT=0.50++0.11; CT+CC=0.56+0.06, P=0.04). CONCLUSIONS: The GNB3 TT genotype was associated with lower LVEF at 6 and 12 months in women with PPCM, and this was particularly evident in blacks. Racial differences in the prevalence and impact of GNB3 TT may contribute to poorer outcomes in black women with PPCM.
BACKGROUND: Black women are at greater risk for peripartum cardiomyopathy (PPCM). The guanine nucleotide-binding proteins β-3 subunit (GNB3) has a polymorphism C825T. The GNB3 TT genotype more prevalent in blacks is associated with poorer outcomes. We evaluated GNB3 genotype and myocardial recovery in PPCM. METHODS AND RESULTS: A total of 97 women with PPCM were enrolled and genotyped for the GNB3 T/C polymorphism. Left ventricular ejection fraction (LVEF) was assessed by echocardiography at entry, 6 and 12 months postpartum. LVEF over time in subjects with the GNB3 TT genotype was compared with those with the C allele overall and in black and white subsets. The cohort was 30% black, age 30+6, LVEF 0.34+0.10 at entry 31+25 days postpartum. The % GNB3 genotype for TT/CT/CC=23/41/36 and differed markedly by race (blacks=52/38/10 versus whites=10/44/46, P<0.001). In subjects with the TT genotype, LVEF at entry was lower (TT=0.31+0.09; CT+CC=0.35+0.09, P=0.054) and this difference increased at 6 (TT=0.45+0.15; CT+CC=0.53+0.08, P=0.002) and 12 months (TT=0.45+0.15; CT+CC=0.56+0.07, P<0.001.). The difference in LVEF at 12 months by genotype was most pronounced in blacks (12 months LVEF for GNB3 TT=0.39+0.16; versus CT+CC=0.53+0.09, P=0.02) but evident in whites (TT=0.50++0.11; CT+CC=0.56+0.06, P=0.04). CONCLUSIONS: The GNB3 TT genotype was associated with lower LVEF at 6 and 12 months in women with PPCM, and this was particularly evident in blacks. Racial differences in the prevalence and impact of GNB3 TT may contribute to poorer outcomes in black women with PPCM.
Authors: A Meirhaeghe; C Bauters; N Helbecque; M Hamon; E McFadden; J M Lablanche; M Bertrand; P Amouyel Journal: Eur Heart J Date: 2001-05 Impact factor: 29.983
Authors: M U Faruque; R M Millis; G M Dunston; J Kwagyan; V Bond; C N Rotimi; T Davis; R Christie; A L Campbell Journal: Int J Sports Med Date: 2009-03-19 Impact factor: 3.118
Authors: Daniel Kurnik; Eitan A Friedman; Mordechai Muszkat; Gbenga G Sofowora; Hong-Guang Xie; William D Dupont; Alastair J J Wood; C Michael Stein Journal: Pharmacogenet Genomics Date: 2008-09 Impact factor: 2.089
Authors: Dennis M McNamara; S William Tam; Michael L Sabolinski; Page Tobelmann; Karen Janosko; Lakshmi Venkitachalam; Elizabeth Ofili; Clyde Yancy; Arthur M Feldman; Jalal K Ghali; Anne L Taylor; Jay N Cohn; Manuel Worcel Journal: J Card Fail Date: 2008-12-23 Impact factor: 5.712
Authors: Dennis M McNamara; Anne L Taylor; S William Tam; Manuel Worcel; Clyde W Yancy; Karen Hanley-Yanez; Jay N Cohn; Arthur M Feldman Journal: JACC Heart Fail Date: 2014-10-08 Impact factor: 12.035
Authors: Olga Corazón Irizarry; Lisa D Levine; Jennifer Lewey; Theresa Boyer; Valerie Riis; Michal A Elovitz; Zolt Arany Journal: JAMA Cardiol Date: 2017-11-01 Impact factor: 14.676
Authors: K M Karaye; N A Ishaq; H Sa'idu; S A Balarabe; M A Talle; M S Isa; U G Adamu; H Umar; H I Okolie; M N Shehu; I Y Mohammed; B Sanni; O S Ogah; I Oboirien; E M Umuerri; A C Mankwe; V Y Shidali; P Njoku; S Dodiyi-Manuel; T T Shogade; T Olunuga; D Ojji; V Josephs; A C Mbakwem; J Tukur; S A Isezuo Journal: ESC Heart Fail Date: 2020-01-28
Authors: Amy Li; K Campbell; S Lal; Y Ge; A Keogh; P S Macdonald; P Lau; John Lai; W A Linke; J Van der Velden; A Field; B Martinac; M Grosser; Cristobal Dos Remedios Journal: Biophys Rev Date: 2022-01-24
Authors: Kamilu M Karaye; Naser A Ishaq; Hadiza Sai'du; Sulaiman A Balarabe; Bashir G Ahmed; Umar G Adamu; Idris Y Mohammed; Isa Oboirien; Ejiroghene M Umuerri; Abaram C Mankwe; Vincent Y Shidali; Sotonye Dodiyi-Manuel; Paschal Njoku; Taiwo Olunuga; Veronica Josephs; Amam C Mbakwem; Okechukwu S Ogah; Jamilu Tukur; Basil Okeahialam; Simon Stewart; Michael Henein; Karen Sliwa Journal: ESC Heart Fail Date: 2021-06-17